A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease

A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease

ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. gov/ct2/show/NCT05821153.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational Neurodegeneration 2023-11, Vol.12 (1), p.54-54, Article 54
Hauptverfasser: Faridar, Alireza, Eid, Abdulmunaim M, Thome, Aaron D, Zhao, Weihua, Beers, David R, Pascual, Maria B, Nakawah, Mohammad O, Roman, Gustavo C, Davis, Charles S, Grundman, Michael, Masdeu, Joseph C, Appel, Stanley H
Format: Artikel
Sprache:eng
Schlagworte:
Advertising executives
Alzheimer Disease - drug therapy
Alzheimer's disease
Chemokines
Cytokines
Dementia
Disease
Drug dosages
Drug therapy
Expansion
Growth factors
Humans
Immunotherapy
Lymphocytes
Pathology
Pilot Projects
Plasma
Silk
T cells
Treatment Outcome
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic. gov/ct2/show/NCT05821153.
ISSN:2047-9158
2047-9158
DOI:10.1186/s40035-023-00387-5